Susan Moran

Biochemistry, Genetics and Molecular BiologyMedicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 4 papers. Top paper: “Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor”.

Ocular Adverse Effects of Infigratinib, a New Fibroblast Growth Factor Receptor Tyrosine Kinase Inhibitor

Ophthalmology(2020)10.1016/j.ophtha.2020.08.026

N/A

0DataRank · unranked

18 citations

Iris R. Hartley, Edmond J. FitzGibbon, Rachel Bishop, Mike Arango, Susan Moran +8 more

Targeted FGFR Blockade for the Treatment of Tumor-Induced Osteomalacia

New England Journal of Medicine(2020)10.1056/nejmc2020399

N/A

0DataRank · unranked

38 citations

Carole B. Miller, Georgios Z. Papadakis, Clemens Bergwitz, Jaydira Del Rivero, Jenny E. Blau +9 more

Reply

Ophthalmology(2021)10.1016/j.ophtha.2021.05.015

N/A

0DataRank · unranked

0 citations

Iris R. Hartley, Edmond J. FitzGibbon, Rachel Bishop, Mike Arango, Susan Moran +8 more

Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study

Clinical Cancer Research(2022)10.1158/1078-0432.ccr-21-2664

N/A

0DataRank · unranked

96 citations

Juan Manuel Sepúlveda-Sánchez, Timothy F. Cloughesy, Miguel Gil‐Gil, Vinay K. Puduvalli, Jeffrey J. Raizer +15 more